Loading clinical trials...
Loading clinical trials...
To measure the effects of Microbial Ecosystem Therapeutics (MET)-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety
An eight week, randomized, placebo controlled trial to assess subjective changes in mood and anxiety symptoms from baseline to after MET-2 treatment in participants with depression, using MADRS, Hamilton Anxiety Rating Scale (HAM-A), and other mood/anxiety scales and to demonstrate a significantly higher proportion of responders in patient who were randomized to receive the active study drug compared to patients who were randomized to receive placebo.
Age
18 - 45 years
Sex
ALL
Healthy Volunteers
No
Providence Care Hospital
Kingston, Ontario, Canada
CAMH
Toronto, Ontario, Canada
Start Date
April 1, 2021
Primary Completion Date
June 1, 2021
Completion Date
June 1, 2021
Last Updated
May 11, 2021
60
ESTIMATED participants
MET-2
DRUG
Placebo
DRUG
Lead Sponsor
NuBiyota
NCT07115329
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07478393